384 related articles for article (PubMed ID: 21420925)
1. Systematic review of the adverse effects of cutaneous leishmaniasis treatment in the New World.
Oliveira LF; Schubach AO; Martins MM; Passos SL; Oliveira RV; Marzochi MC; Andrade CA
Acta Trop; 2011 May; 118(2):87-96. PubMed ID: 21420925
[TBL] [Abstract][Full Text] [Related]
2. An open label randomized clinical trial comparing the safety and effectiveness of one, two or three weekly pentamidine isethionate doses (seven milligrams per kilogram) in the treatment of cutaneous leishmaniasis in the Amazon Region.
Gadelha EPN; Ramasawmy R; da Costa Oliveira B; Morais Rocha N; de Oliveira Guerra JA; Allan Villa Rouco da Silva G; Gabrielle Ramos de Mesquita T; Chrusciak Talhari Cortez C; Chrusciak Talhari A
PLoS Negl Trop Dis; 2018 Oct; 12(10):e0006850. PubMed ID: 30379814
[TBL] [Abstract][Full Text] [Related]
3. Cutaneous leishmaniasis treatment.
Minodier P; Parola P
Travel Med Infect Dis; 2007 May; 5(3):150-8. PubMed ID: 17448941
[TBL] [Abstract][Full Text] [Related]
4. A phase II study to evaluate the safety and efficacy of topical 3% amphotericin B cream (Anfoleish) for the treatment of uncomplicated cutaneous leishmaniasis in Colombia.
López L; Vélez I; Asela C; Cruz C; Alves F; Robledo S; Arana B
PLoS Negl Trop Dis; 2018 Jul; 12(7):e0006653. PubMed ID: 30044792
[TBL] [Abstract][Full Text] [Related]
5. [Successful treatment of cutaneous leishmaniasis with amphotericin B; a case of unresponsive to pentavalent antimony therapy].
Yeşilova Y; Turan E; Sürücü HA; Aksoy M; Özbilgin A
Turkiye Parazitol Derg; 2015 Mar; 39(1):63-5. PubMed ID: 25917587
[TBL] [Abstract][Full Text] [Related]
6. A pilot study comparing low-dose liposomal amphotericin B with N-methyl glucamine for the treatment of American cutaneous leishmaniasis.
Motta JO; Sampaio RN
J Eur Acad Dermatol Venereol; 2012 Mar; 26(3):331-5. PubMed ID: 21492255
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic options for old world cutaneous leishmaniasis and new world cutaneous and mucocutaneous leishmaniasis.
Monge-Maillo B; López-Vélez R
Drugs; 2013 Nov; 73(17):1889-920. PubMed ID: 24170665
[TBL] [Abstract][Full Text] [Related]
8. Clinical Response with intralesional Amphotericin B in the treatment of old world cutaneous leishmaniasis: a preliminary report.
Mushtaq S; Dogra D; Dogra N
Dermatol Ther; 2016 Nov; 29(6):398-405. PubMed ID: 27477764
[TBL] [Abstract][Full Text] [Related]
9. Intralesional antimony for single lesions of bolivian cutaneous leishmaniasis.
Soto J; Rojas E; Guzman M; Verduguez A; Nena W; Maldonado M; Cruz M; Gracia L; Villarroel D; Alavi I; Toledo J; Berman J
Clin Infect Dis; 2013 May; 56(9):1255-60. PubMed ID: 23390069
[TBL] [Abstract][Full Text] [Related]
10. American tegumentary leishmaniasis: severe side effects of pentavalent antimonial in a patient with chronic renal failure.
Marques SA; Merlotto MR; Ramos PM; Marques MEA
An Bras Dermatol; 2019 Jul; 94(3):355-357. PubMed ID: 31365669
[TBL] [Abstract][Full Text] [Related]
11. Successful treatment of cutaneous leishmaniasis with lipid formulations of amphotericin B in two immunocompromised patients.
Amato VS; Rabello A; Rotondo-Silva A; Kono A; Maldonado TP; Alves IC; Floeter-Winter LM; Neto VA; Shikanai-Yasuda MA
Acta Trop; 2004 Oct; 92(2):127-32. PubMed ID: 15350864
[TBL] [Abstract][Full Text] [Related]
12. Treatment of New World cutaneous leishmaniasis--a systematic review with a meta-analysis.
Tuon FF; Amato VS; Graf ME; Siqueira AM; Nicodemo AC; Amato Neto V
Int J Dermatol; 2008 Feb; 47(2):109-24. PubMed ID: 18211479
[TBL] [Abstract][Full Text] [Related]
13. Comparison of meglumine antimoniate and pentamidine for peruvian cutaneous leishmaniasis.
Andersen EM; Cruz-Saldarriaga M; Llanos-Cuentas A; Luz-Cjuno M; Echevarria J; Miranda-Verastegui C; Colina O; Berman JD
Am J Trop Med Hyg; 2005 Feb; 72(2):133-7. PubMed ID: 15741547
[TBL] [Abstract][Full Text] [Related]
14. [Management of American cutaneous leishmaniasis. Outcome apropos of 326 cases treated with high-dose pentamidine isethionate].
Lightburn E; Morand JJ; Meynard JB; Kraemer P; Chaudier B; Pages F; Garnotel E; Patte JH; Banzet S; Dampierre H; Lepage J; Morillon M; Boutin JP; Hovette P; Chouc C
Med Trop (Mars); 2003; 63(1):35-44. PubMed ID: 12891748
[TBL] [Abstract][Full Text] [Related]
15. [Canine leishmaniasis: evolution of the chemotherapeutic protocols].
Oliva G; Foglia Manzillo V; Pagano A
Parassitologia; 2004 Jun; 46(1-2):231-4. PubMed ID: 15305724
[TBL] [Abstract][Full Text] [Related]
16. Pentamidine isethionate as treatment and secondary prophylaxis for disseminated cutaneous leishmaniasis during HIV infection: case report.
Calza L; Marinacci G; Manfredi R; Colangeli V; Fortunato L; Chiodo F
J Chemother; 2001 Dec; 13(6):653-7. PubMed ID: 11806628
[TBL] [Abstract][Full Text] [Related]
17. Successful liposomal amphotericin B treatment of Leishmania braziliensis cutaneous leishmaniasis.
Brown M; Noursadeghi M; Boyle J; Davidson RN
Br J Dermatol; 2005 Jul; 153(1):203-5. PubMed ID: 16029352
[TBL] [Abstract][Full Text] [Related]
18. Use of the intramuscular route to administer pentamidine isethionate in Leishmania guyanensis cutaneous leishmaniasis increases the risk of treatment failure.
Christen JR; Bourreau E; Demar M; Lightburn E; Couppié P; Ginouvès M; Prévot G; Gangneux JP; Savini H; de Laval F; Pommier de Santi V; Briolant S
Travel Med Infect Dis; 2018; 24():31-36. PubMed ID: 29482012
[TBL] [Abstract][Full Text] [Related]
19. Pentamidine, the drug of choice for the treatment of cutaneous leishmaniasis in Surinam.
Lai A Fat EJ; Vrede MA; Soetosenojo RM; Lai A Fat RF
Int J Dermatol; 2002 Nov; 41(11):796-800. PubMed ID: 12453009
[TBL] [Abstract][Full Text] [Related]
20. Liposomal amphotericin B in travelers with cutaneous and muco-cutaneous leishmaniasis: Not a panacea.
Guery R; Henry B; Martin-Blondel G; Rouzaud C; Cordoliani F; Harms G; Gangneux JP; Foulet F; Bourrat E; Baccard M; Morizot G; Consigny PH; Berry A; Blum J; Lortholary O; Buffet P;
PLoS Negl Trop Dis; 2017 Nov; 11(11):e0006094. PubMed ID: 29155816
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
